What I Came to Build: Aimee Mishkin

In 2020, Kymera’s regulatory function was a team of one.

Aimee Mishkin was the first regulatory hire, joining just as the clinical organization was taking shape and the earliest degrader programs were moving toward the clinic. There was no well-worn path for developing degrader medicines, so Aimee set out to help build one.

She had done regulatory work across many companies, disease areas and stages of development, but the problems that energize her most are the ones she hasn’t seen before. For Aimee, every program starts with a fresh set of questions that require digging deep into the science, picturing a path that doesn’t exist yet and bringing people across functions together to build it.

Six years later, that approach has shaped Kymera’s pipeline. As the company continues to grow, she keeps making room for new perspectives that challenge established thinking, because that’s how a new generation of medicines moves forward.

Watch her story: